The activation of the Wnt/β-catenin signaling pathway in oval cells after liver injury is implicated in hepatocarcinogenesis.Diwu Yanggan capsule is a Chinese herbal medicine that has been used for treating liver dis...The activation of the Wnt/β-catenin signaling pathway in oval cells after liver injury is implicated in hepatocarcinogenesis.Diwu Yanggan capsule is a Chinese herbal medicine that has been used for treating liver disorder.The present study aimed to examine the mechanism by which Diwu Yanggan inhibits liver carcinogenesis,and the involvement of the Wnt/β-catenin signaling pathway.Diwu Yanggan capsule was administered to 2-acetaminofluorene/partial hepatectomy(2-AAF/PH)rats,a murine model of liver injury.The biomarkers of oval cells and key proteins in the Wnt/p-catenin signaling pathway were assessed on postoperative day 8,10,14,17,19 and 22.The results showed that treatment with Diwu Yanggan was associated with reduced expression of oval cell and stem cell biomarkers in the 2-AAF/PH animals.The expression pattern of key proteins in the Wnt/β-catenin pathway was altered in Diwu Yanggan-treated animals,indicating that the Diwu Yanggan treatment accelerated the activation of the Wnt/β-catenin pathway in the initial stage and contributed to its deactivation in the later stage.Histological findings indicated that hepatocyte proliferation was suppressed in Diwu Yanggan-treated animals,compared with untreated 2-AAF/PH animals.Taken together,Diwu Yanggan capsule may reduce the risk of hepatocarcinogenesis by modulating the Wnt/β-catenin signaling pathway.展开更多
The role of NF-κB and the NLRP3 inflammasome in the chronic inflammatory microenvironment of non-alcoholic steatohepatitis(NASH)has been posited as crucial.The Yanggan Jiangmei Formula(YGJMF)has shown promise in amel...The role of NF-κB and the NLRP3 inflammasome in the chronic inflammatory microenvironment of non-alcoholic steatohepatitis(NASH)has been posited as crucial.The Yanggan Jiangmei Formula(YGJMF)has shown promise in ameliorating hepatic steatosis in NASH patients,yet its pharmacological mechanisms remain largely unexplored.This study was conducted to investigate the efficacy of YGJMF in NASH and to elucidate its pharmacological underpinnings.To simulate NASH both in vivo and in vitro,high-fat-diet(HFD)rats and HepG2 cells stimulated with free fatty acids(FFAs)were utilized.The severity of liver injury and lipid deposition was assessed using serum indicators,histopathological staining,micro-magnetic resonance imaging(MRI),and the liver-tomuscle signal intensity ratio(SIRL/M).Furthermore,a combination of enzyme-linked immunosorbent assay(ELISA),immunohistochemistry(IHC),immunofluorescence,real-time quantitative polymerase chain reaction(RT-qPCR),and Western blotting analyses was employed to investigate the NF-κB/NLRP3 signaling pathway and associated cytokine levels.The results from liver pathology,MRI assessments,and biochemical tests in rat models demonstrated YGJMF’s significant effectiveness in reducing liver damage and lipid accumulation.Additionally,YGJMF markedly reduced hepatocyte inflammation by downregulating inflammatory cytokines in both liver tissue and serum.Furthermore,YGJMF was found to disrupt NF-κB activation,consequently inhibiting the assembly of the NLRP3 inflammasome in both the in vitro and in vivo models.The preliminary findings of this study suggest that YGJMF may alleviate hepatic steatosis and inhibit the NF-κB/NLRP3 signaling pathway,thereby exerting anti-inflammatory effects in NASH.展开更多
Background and Aims:The aim was to evaluate the efficacy and safety of Yanggan Jian(YGJ)in HBV-infected patients with decompensated cirrhosis.Methods:This randomized,double-blind controlled trial enrolled 160 patients...Background and Aims:The aim was to evaluate the efficacy and safety of Yanggan Jian(YGJ)in HBV-infected patients with decompensated cirrhosis.Methods:This randomized,double-blind controlled trial enrolled 160 patients with HBV-related decompensated cirrhosis who were already receiving or about to start antiviral therapy.Patients were randomly assigned to receive YGJ or placebo for 24 weeks,and were followed-up to 36 weeks.The primary outcome was the proportion of patients with a≥2 point reduction in Child-Turcotte-Pugh(CTP)score from baseline at week 24.Secondary outcomes were CTP class and score,serum liver function indices,mortality,incidence of hepatocellular carcinoma and variceal bleeding.Results:The proportion of patients with a CTP score reduction≥2 was significantly greater in the YGJ than in the placebo group(p=0.009);the percentage of patients with CTP class C was significantly less than that in the placebo group(p<0.05),and the YGJ group had a significantly greater mean change from baseline in CTP score at week 24(p=0.034).The improvement in measured values and change from baseline of prothrombin time,serum albumin,platelets,cholinesterase,international normalized ratio,and activated partial thromboplastin time were significantly better with YGJ than with placebo.Between-group differences in cumulative rates of variceal bleeding,hepatocellular carcinoma,death,or the frequency of any adverse event(AE),AEs related to treatment,or discontinuation because of AEs were not significant.Conclusions:YGJ significantly improved CTP scores and hepatic synthetic and reserve function in patients with HBV-related decompensated cirrhosis,and was safe and well tolerated.展开更多
Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and random...Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and randomized into two groups according to the random number table in a ratio of 3：1, with 8 cases eventually dropping out. The symptoms, signs, liver function markers, blood lipids, iconographic indices and clinical comprehensive efficacy after a 12-week treatment course were assessed in 101 patients treated with TZYGD in the treated group and 29 patients treated with Thiola in the control group. Results： The total effective rate in the treated group and the control group was 81.19% and 68.97%, respectively, showing a significant difference between the two groups with the former being significantly higher than the latter （P〈0.05）. Moreover, the improvements in the symptoms, signs, liver function, blood lipids and iconographic indices in the treated group were favorable with no serious adverse reactions. Conclusion： TZYGD is effective and highly safe in treating non-alcoholic fatty liver.展开更多
Objective: To assess the efficacy of Yanggan Aoping Mixture (养肝澳平, YGAPM) in treatinghepatitis B. Methods: Patients suffered from chronic hepatitis B were treated with YGAPM. Observe theirshort-- and long--term ef...Objective: To assess the efficacy of Yanggan Aoping Mixture (养肝澳平, YGAPM) in treatinghepatitis B. Methods: Patients suffered from chronic hepatitis B were treated with YGAPM. Observe theirshort-- and long--term efficacy and the change of serum hepatitis B virus marker. In experiment, the effects ofYGAPM in treating rat's liver injury as well as HBV--infected tree shrew and duck HBV--infected ducks were observed. Results: In 79 cases of chronic persistent hepatitis, the markedly effective rate was 60. 76%, and further raised to 70. 00 % in follow-up study in 40 cases. In 73 cases of chronic active hepatitis, the markedly effective rate was 60. 27%, and further raised to 62. 50% in 32 follow-up cases. In the treatment group, 85 of the119 cases (71. 43 % ) with HBeAg-positive were converted to negative. Whereas in the control group, only 40 of89 HBeAg-positive cases (44. 94 % ) were converted to negative, P < 0. 01. Results of experimental studyshowed that negative conversion rate of tree shrew infected with HBV marker was raised, while the duck HBVDNA in infected duck blood was inhibited. Those compared with the control group separately, the differencewas markedly significant. Conclusion: YGAPM is an effective drug in treating chronic hepatitis B, and it couldeffectively convert the marker to negative.展开更多
基金the National Natural Science Foundation of China(Nos.81703973,81973669,81703912,and 81603484)National Key R&D Program of China(No.2018YFC1705600)+4 种基金Research Projects of Key Disease for Practice Development of National TCM Clinical Research Bases(No.JDZX2015172)Science and Technology Research Program of Hubei Education Department for Young Investigators(No.Q20172003)The Green Seedlings Program of Hubei University of Chinese Medicine(No.HUCM[2016]224)Special Program for Advanced Researchers of Hubei University of Chinese Medicine(No.5114-100724)Li Han-min National Famous Old Chinese Medicine Experts Inheritance Studio.
文摘The activation of the Wnt/β-catenin signaling pathway in oval cells after liver injury is implicated in hepatocarcinogenesis.Diwu Yanggan capsule is a Chinese herbal medicine that has been used for treating liver disorder.The present study aimed to examine the mechanism by which Diwu Yanggan inhibits liver carcinogenesis,and the involvement of the Wnt/β-catenin signaling pathway.Diwu Yanggan capsule was administered to 2-acetaminofluorene/partial hepatectomy(2-AAF/PH)rats,a murine model of liver injury.The biomarkers of oval cells and key proteins in the Wnt/p-catenin signaling pathway were assessed on postoperative day 8,10,14,17,19 and 22.The results showed that treatment with Diwu Yanggan was associated with reduced expression of oval cell and stem cell biomarkers in the 2-AAF/PH animals.The expression pattern of key proteins in the Wnt/β-catenin pathway was altered in Diwu Yanggan-treated animals,indicating that the Diwu Yanggan treatment accelerated the activation of the Wnt/β-catenin pathway in the initial stage and contributed to its deactivation in the later stage.Histological findings indicated that hepatocyte proliferation was suppressed in Diwu Yanggan-treated animals,compared with untreated 2-AAF/PH animals.Taken together,Diwu Yanggan capsule may reduce the risk of hepatocarcinogenesis by modulating the Wnt/β-catenin signaling pathway.
基金supported by the National Natural Science Foundation of China(No.8200151236)the Postgraduate Research Practice Innovation Program of Jiangsu Province(No.KYCX22_1903)the Outstanding Clinical Talents of Traditional Chinese Medicine in Jiangsu Province(No.18,Jiangsu Science and Education of Traditional Chinese Medicine[2017]).
文摘The role of NF-κB and the NLRP3 inflammasome in the chronic inflammatory microenvironment of non-alcoholic steatohepatitis(NASH)has been posited as crucial.The Yanggan Jiangmei Formula(YGJMF)has shown promise in ameliorating hepatic steatosis in NASH patients,yet its pharmacological mechanisms remain largely unexplored.This study was conducted to investigate the efficacy of YGJMF in NASH and to elucidate its pharmacological underpinnings.To simulate NASH both in vivo and in vitro,high-fat-diet(HFD)rats and HepG2 cells stimulated with free fatty acids(FFAs)were utilized.The severity of liver injury and lipid deposition was assessed using serum indicators,histopathological staining,micro-magnetic resonance imaging(MRI),and the liver-tomuscle signal intensity ratio(SIRL/M).Furthermore,a combination of enzyme-linked immunosorbent assay(ELISA),immunohistochemistry(IHC),immunofluorescence,real-time quantitative polymerase chain reaction(RT-qPCR),and Western blotting analyses was employed to investigate the NF-κB/NLRP3 signaling pathway and associated cytokine levels.The results from liver pathology,MRI assessments,and biochemical tests in rat models demonstrated YGJMF’s significant effectiveness in reducing liver damage and lipid accumulation.Additionally,YGJMF markedly reduced hepatocyte inflammation by downregulating inflammatory cytokines in both liver tissue and serum.Furthermore,YGJMF was found to disrupt NF-κB activation,consequently inhibiting the assembly of the NLRP3 inflammasome in both the in vitro and in vivo models.The preliminary findings of this study suggest that YGJMF may alleviate hepatic steatosis and inhibit the NF-κB/NLRP3 signaling pathway,thereby exerting anti-inflammatory effects in NASH.
基金supported by the National Natural Science Foundation of China (82130120)Shanghai Science and Technology Committee Rising-Star Program (19QA1408900)+1 种基金WBE Liver Fibrosis Foundation (CFHPC2020010)Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (SGXZ-201908 and SGKJLC-202013).
文摘Background and Aims:The aim was to evaluate the efficacy and safety of Yanggan Jian(YGJ)in HBV-infected patients with decompensated cirrhosis.Methods:This randomized,double-blind controlled trial enrolled 160 patients with HBV-related decompensated cirrhosis who were already receiving or about to start antiviral therapy.Patients were randomly assigned to receive YGJ or placebo for 24 weeks,and were followed-up to 36 weeks.The primary outcome was the proportion of patients with a≥2 point reduction in Child-Turcotte-Pugh(CTP)score from baseline at week 24.Secondary outcomes were CTP class and score,serum liver function indices,mortality,incidence of hepatocellular carcinoma and variceal bleeding.Results:The proportion of patients with a CTP score reduction≥2 was significantly greater in the YGJ than in the placebo group(p=0.009);the percentage of patients with CTP class C was significantly less than that in the placebo group(p<0.05),and the YGJ group had a significantly greater mean change from baseline in CTP score at week 24(p=0.034).The improvement in measured values and change from baseline of prothrombin time,serum albumin,platelets,cholinesterase,international normalized ratio,and activated partial thromboplastin time were significantly better with YGJ than with placebo.Between-group differences in cumulative rates of variceal bleeding,hepatocellular carcinoma,death,or the frequency of any adverse event(AE),AEs related to treatment,or discontinuation because of AEs were not significant.Conclusions:YGJ significantly improved CTP scores and hepatic synthetic and reserve function in patients with HBV-related decompensated cirrhosis,and was safe and well tolerated.
文摘Objective： To observe the clinical efficacy and safety of Tiaozhi Yanggan Decoction （调脂养肝汤,TZYGD） in treating non-alcoholic fatty liver. Methods： One hundred and thirty-eight patients were enrolled and randomized into two groups according to the random number table in a ratio of 3：1, with 8 cases eventually dropping out. The symptoms, signs, liver function markers, blood lipids, iconographic indices and clinical comprehensive efficacy after a 12-week treatment course were assessed in 101 patients treated with TZYGD in the treated group and 29 patients treated with Thiola in the control group. Results： The total effective rate in the treated group and the control group was 81.19% and 68.97%, respectively, showing a significant difference between the two groups with the former being significantly higher than the latter （P〈0.05）. Moreover, the improvements in the symptoms, signs, liver function, blood lipids and iconographic indices in the treated group were favorable with no serious adverse reactions. Conclusion： TZYGD is effective and highly safe in treating non-alcoholic fatty liver.
文摘Objective: To assess the efficacy of Yanggan Aoping Mixture (养肝澳平, YGAPM) in treatinghepatitis B. Methods: Patients suffered from chronic hepatitis B were treated with YGAPM. Observe theirshort-- and long--term efficacy and the change of serum hepatitis B virus marker. In experiment, the effects ofYGAPM in treating rat's liver injury as well as HBV--infected tree shrew and duck HBV--infected ducks were observed. Results: In 79 cases of chronic persistent hepatitis, the markedly effective rate was 60. 76%, and further raised to 70. 00 % in follow-up study in 40 cases. In 73 cases of chronic active hepatitis, the markedly effective rate was 60. 27%, and further raised to 62. 50% in 32 follow-up cases. In the treatment group, 85 of the119 cases (71. 43 % ) with HBeAg-positive were converted to negative. Whereas in the control group, only 40 of89 HBeAg-positive cases (44. 94 % ) were converted to negative, P < 0. 01. Results of experimental studyshowed that negative conversion rate of tree shrew infected with HBV marker was raised, while the duck HBVDNA in infected duck blood was inhibited. Those compared with the control group separately, the differencewas markedly significant. Conclusion: YGAPM is an effective drug in treating chronic hepatitis B, and it couldeffectively convert the marker to negative.
